10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
PFIZER INC | |||
Ticker: PFE Fiscal Year: 2010 | |||
Consolidated Statements of Income | |||
Period Ending Dec 31, 2010 10-K (Filed: Feb 28, 2011) | |||
| (In Millions) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2010 | Dec 31, 2009 | Dec 31, 2008 | |
| Revenues | $ 67,809 | 50,009 | 48,296 |
| Costs and expenses: | |||
| Cost of Sales | 16,279 | 8,888 | 8,112 |
| Selling, informational and administrative expenses | 19,614 | 14,875 | 14,537 |
| Research and development expenses | 9,413 | 7,845 | 7,945 |
| Amortization of intangible assets | 5,404 | 2,877 | 2,668 |
| Acquisition-related in-process research and development charges | 125 | 68 | 633 |
| Restructuring charges and certain acquisition - related costs | 3,214 | 4,337 | 2,675 |
| Other deductions - net | 4,338 | 292 | 2,032 |
| Income from continuing operations before provision for taxes on income | 9,422 | 10,827 | 9,694 |
| Provision for taxes on income | 1,124 | 2,197 | 1,645 |
| Income from continuing operations | 8,298 | 8,630 | 8,049 |
| Discontinued operations - net of tax | (9) | 14 | 78 |
| Net income before allocation to noncontrolling interests | 8,289 | 8,644 | 8,127 |
| Less: Net income attributable to noncontrolling interests | 32 | 9 | 23 |
| Net income attributable to Pfizer Inc. | 8,257 | 8,635 | 8,104 |
| Earnings per common share - basic | |||
| Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share) | 1.03 | 1.23 | 1.19 |
| Discontinued operations - net of tax (in dollars per share) | 0.01 | ||
| Net income attributable to Pfizer Inc. common shareholders (in dollars per share) | 1.03 | 1.23 | 1.20 |
| Earnings per common share - diluted | |||
| Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share) | 1.02 | 1.23 | 1.19 |
| Discontinued operations - net of tax (in dollars per share) | 0.01 | ||
| Net income attributable to Pfizer Inc. common shareholders (in dollars per share) | 1.02 | 1.23 | 1.20 |
| Weighted-average shares - basic (in shares) | 8,036 | 7,007 | 6,727 |
| Weighted-average shares - diluted (in shares) | 8,074 | 7,045 | 6,750 |
| External Links | |
| PFIZER INC (PFE) Fiscal Year 2010 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |